Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics Inc.||4||0.00||N/A||-0.81||0.00|
|Conatus Pharmaceuticals Inc.||1||0.42||N/A||-0.57||0.00|
Table 1 showcases the gross revenue, earnings per share and valuation of Brainstorm Cell Therapeutics Inc. and Conatus Pharmaceuticals Inc.
Table 2 represents Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics Inc.||0.00%||-236.6%||-115.3%|
|Conatus Pharmaceuticals Inc.||0.00%||-81%||-32.8%|
Risk & Volatility
Brainstorm Cell Therapeutics Inc. has a 1.19 beta, while its volatility is 19.00%, thus making it more volatile than Standard and Poor’s 500. Conatus Pharmaceuticals Inc.’s 120.00% more volatile than Standard and Poor’s 500 volatility due to the stock’s 2.2 beta.
Brainstorm Cell Therapeutics Inc.’s Current Ratio is 1 while its Quick Ratio is 1. On the competitive side is, Conatus Pharmaceuticals Inc. which has a 2.4 Current Ratio and a 2.4 Quick Ratio. Conatus Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.
The table delivered features the ratings and recommendations for Brainstorm Cell Therapeutics Inc. and Conatus Pharmaceuticals Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics Inc.||0||0||1||3.00|
|Conatus Pharmaceuticals Inc.||0||0||0||0.00|
Brainstorm Cell Therapeutics Inc.’s upside potential is 121.67% at a $9 average price target. Meanwhile, Conatus Pharmaceuticals Inc.’s average price target is $1.5, while its potential upside is 261.01%. Based on the data delivered earlier, Conatus Pharmaceuticals Inc. is looking more favorable than Brainstorm Cell Therapeutics Inc., analysts opinion.
Institutional & Insider Ownership
Brainstorm Cell Therapeutics Inc. and Conatus Pharmaceuticals Inc. has shares owned by institutional investors as follows: 11.4% and 25.1%. Brainstorm Cell Therapeutics Inc.’s share owned by insiders are 0.6%. Insiders Comparatively, owned 3.34% of Conatus Pharmaceuticals Inc. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Brainstorm Cell Therapeutics Inc.||0.75%||-0.25%||2.82%||8.97%||-2.43%||12.96%|
|Conatus Pharmaceuticals Inc.||-9.55%||17.93%||-61.64%||-86.16%||-91.73%||-81.6%|
For the past year Brainstorm Cell Therapeutics Inc. had bullish trend while Conatus Pharmaceuticals Inc. had bearish trend.
Conatus Pharmaceuticals Inc. beats on 6 of the 9 factors Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.